Phrixus Pharmaceuticals

The experimental drug Carmeseal, given at very low doses, improved signs of respiratory function in a mouse model of Duchenne muscular dystrophy

posted on July 25, 2012 - 4:55pm
Phrixus Pharmaceuticals in Ann Arbor, Mich., reported July 19, 2012, that its experimental drug Carmeseal demonstrated a beneficial effect on the diaphragm (the primary breathing muscle) in mice with a disease resembling Duchenne muscular dystrophy (DMD).

New content is being added every day. Please check back again.